Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Whole body hyperthermia induction of soluble tumor necrosis factor receptors: implications for rheumatoid diseases. J Rheumatol 1999 Dec;26(12):2513-6

Date

12/22/1999

Pubmed ID

10606355

Scopus ID

2-s2.0-0032733772 (requires institutional sign-in at Scopus site)   6 Citations

Abstract

OBJECTIVE: To test the hypothesis that 41.8 degrees C x 60 min whole body hyperthermia (WBH) induces increased serum levels of soluble necrosis factor receptors (sTNF-R).

METHODS: We tested the serum of cancer patients for changes in sTNF-RI and RII levels, as a function of time, pre and post: (1) WBH alone, (2) WBH and chemotherapy, i.e., melphalan (L-PAM), and (3) L-PAM alone.

RESULTS: For sTNF-RI there was a marked increase (over pre-treatment values, i.e., 86%) in serum levels after WBH alone (n = 3), which peaked 2.5 h post-WBH; L-PAM (iv) only resulted in a dip in sTNF-RI seen 40 min postadministration; the combination (WBH + L-PAM), resulted in both the dip at 40 min and the increase at 2.5 h post-treatment. For sTNF-RII both WBH alone (n = 3) and WBH + L-PAM (n = 2), there was an increase in receptor serum levels of 25% and 30%, respectively, which peaked 5.5 h post-treatment, and remained elevated at 24 h. L-PAM alone resulted in a dip in levels only at 40 min post-treatment. sTNF-RI and RII levels returned to baseline values within 7 days post-treatment.

CONCLUSION: 41.8 degrees C WBH results in transient increases in TNF-RI and RII. These results may have therapeutic implications for the application of WBH to TNF mediated disease processes.

Author List

Robins HI, Grosen E, Katschinski DM, Longo W, Tiggelaar CL, Kutz M, Winawer J, Graziano F

Author

Walter L. Longo MD Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Antineoplastic Agents, Alkylating
Body Temperature
Cohort Studies
Female
Humans
Hyperthermia, Induced
Interleukin-10
Male
Melanoma
Melphalan
Middle Aged
Pancreatic Neoplasms
Receptors, Tumor Necrosis Factor
Rheumatic Diseases
Skin Neoplasms
Solubility
Tumor Necrosis Factor-alpha